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Background: This phase III trial was to compare 5-fluorouracil (5-FU), adriamycin, and polyadenylic–polyuridylic acid
(poly A:U) against 5-fluorouracil plus adriamycin (FA) for operable gastric cancer.
Patients and methods: From 1984 to 1989, patients who had D2–3 curative resection were randomly assigned to
receive chemotherapy or chemoimmunotherapy. Chemotherapy consisted of 12 mg/kg 5-FU every week for 18
months and 40 mg/m2 adriamycin every 3 weeks for 12 cycles. Chemoimmunotherapy consisted of FA plus 100 mg of
poly A:U weekly for six cycles and was followed 6 months later by six weekly 50-mg booster injections.
Results: A total of 292 patients were enrolled. After excluding 12 ineligible patients, 142 and 138 patients were
allocated to each treatment. Patients were balanced with prognostic variables: age, sex, tumor location, differentiation,
degree of tumor invasion (T2–T4a), and lymph node status (N0–N2). During the 15-year follow-up,
chemoimmunotherapy significantly prolonged overall (P = 0.013) and recurrence-free (P = 0.005) survivals compared
with chemotherapy alone. The survival benefits were prominent in the subset of patients with T3/T4a, N2, or stage III.
Treatments were generally well tolerated in both arms.
Conclusions: These results indicate a survival advantage of chemoimmunotherapy with a regimen of FA and poly
A:U in curatively resected gastric adenocarcinoma.
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introduction
Gastric cancer remains a worldwide health problem [1]. In
Korea, gastric cancer is the leading cause of cancer-related
deaths [2]. The most effective treatment for gastric cancer is
radical gastrectomy. A substantial number of patients, however,
eventually die of recurrence after curative resection. In an
attempt to improve the survival of gastric cancer patients who
have undergone curative resection, a number of randomized
trials have investigated the role of adjuvant chemotherapy or
immunotherapy. Meta-analyses on adjuvant chemotherapy for
gastric cancer have indicated that adjuvant chemotherapy
does not significantly increase survival in Western populations,
but it does have an effect on Asian populations [3, 4]. At the
initiation of the present trial, Moertel et al. [5] indicated that
the combination of 5-fluorouracil (5-FU) and adriamycin
would result in the most favorable survival rate for patients
with advanced gastric cancer. Thus, beginning in the early
1980s, our institution treated patients who had locally
advanced gastric cancer with 5-fluorouracil plus adriamycin
(FA) as the adjuvant chemotherapy.
Polyadenylic–polyuridylic acid (poly A:U), a nontoxic,
synthetic double-stranded complex of polyribonucleotides, has
proved to be a potent immunomodulator for both humoral
and cell-mediated immune responses [6–8]. The first adjuvant
trial of poly A:U in human cancer was conducted on patients
with operable breast cancer and demonstrated a significant
survival benefit over surgery alone [9]. Moreover, poly A:U, in
addition to chemotherapy, has been shown to exert
a synergistic antitumor effect in experimental tumor models
[10]. For gastric cancer, no immunomodulatory role of poly
A:U has yet been identified. To examine the effect of poly A:U
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on gastric cancer, we conducted a prospective phase III trial
of FA plus poly A:U chemoimmunotherapy versus FA
chemotherapy alone after curative resection of gastric cancer.
patients and methods
eligibility criteria
Eligibility criteria included (i) pathologically proven gastric
adenocarcinoma treated by curative surgery; (ii) no history of previous
chemotherapy or radiotherapy; (iii) no previous immunosuppressive
treatment within 3 months of surgery; (iv) Eastern Cooperative Oncology
Group performance status of less than or equal to one; (v) adequate
function of bone marrow (white blood cell ‡ 4 · 103/ll, platelets ‡ 100 ·
103/ll, and hemoglobin ‡ 9.0 g/dl), kidney (serum creatinine level £ 1.5
mg/dl), and liver (increase in serum bilirubin £ 2.0 mg/dl and transaminase
£ 2 · upper normal limit); (vi) no history of congestive cardiac failure
(CHF); and (vii) no history of other active malignancies. Patients who had
early (T1N0–2) or advanced tumors (T4bN0–2 or T2–4aN3) were ineligible
even if these were resected en bloc with the primary tumor (Figure 1). Other
exclusion criteria included (i) age >70 years, (ii) tumor excised from
discontinuous sites, or (iii) presence of ascites. Patients were enrolled after
pathologic staging was completed and the patient’s postoperative
condition improved to a point that would permit chemotherapy (usually
2–4 weeks of postoperation). Patients who had not sufficiently recovered
by the 45th postoperative day were ineligible. All patients provided
written informed consent.
curative surgery
Curative resection (D2/D3) was defined as stipulated by the Japanese
Research Society for Gastric Cancer and includes (i) total or subtotal
gastrectomy with systemic lymphadenectomy and omentectomy, (ii) no
involvement of surgical stumps, (iii) sufficient lymphatic dissection
(R number ‡ N number), (iv) no distant metastasis, (v) removal of
involved adjacent organs and structures by combined en bloc resection, and
(vi) no gross residual disease [11]. All surgeries were carried out by five
surgeons according to the standardized resection technique in two affiliated
hospitals.
pathology
Pathologic reviews were done to establish the histological subtypes, tumor
differentiation, tumor depth (T), and number of total resected and
metastatic lymph nodes with systemic grouping (N0–N2). Tumor subtypes
and differentiation were evaluated according to the World Health
Organization (WHO) criteria and tumor staging was made according to the
tumor–node–metastasis staging system of the American Joint Cancer
Committee (AJCC, 1984) [12, 13].
study design
Patients were randomly assigned to receive either chemotherapy alone or
chemoimmunotherapy using random tables. Chemotherapy began within
6 weeks of surgery (Figure 2). Chemotherapy consisted of 12 mg/kg
5-FU weekly for 18 months and 40 mg/m2 adriamycin every 3 weeks for
a total of 12 cycles. In patients receiving combined chemoimmunotherapy,
patients followed the FA regimen above, and poly A:U (100 mg weekly
for six cycles) treatments were administered beginning 4 days after the
initiation of chemotherapy. Six months later, weekly 50-mg poly A:U
booster injections were administered for six cycles (Figure 2). If
a patient’s leukocyte count fell below 3 · 103/ll or the platelet count
fell below 100 · 103/ll, treatment was delayed until recovery.
The primary end point was overall survival (OS), and the secondary end
points were recurrence-free survival (RFS), gastric cancer-specific survival,
and toxicity. OS was defined as the time from randomization to death by
any cause or the date at which the patient was last confirmed. RFS was
defined as the time from randomization to gastric cancer recurrence or the
last date at which the patient was followed up. Causes of death other than
gastric cancer recurrence were considered as censoring for recurrence.
Gastric cancer-specific survival duration was defined from randomization
to death from gastric cancer recurrence or from toxicity of treatment.
toxicity and follow-up evaluation
Adverse effects were graded by WHO criteria [14]. At the end of the
planned adjuvant therapy, a follow-up study was carried out with chest
radiography, computed tomography (CT) of abdomen–pelvis, radionuclide
bone scan, and esophagogastroduodenoscopy. Patients were followed up
monthly for the first 3 months, every 3 months for the next 2 years, every 6
months until the 10th year after surgery, and then every year thereafter.
Stage I, III T1 N0-2 Ineligible
II T2-3 N0 Eligible
III T2 N1-2
T3 N0-2 Eligible
T4a
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Figure 1. Eligible stages (gray area) for (A) gastric cancer [tumor–node–metastasis staging: American Joint Cancer Committee (AJCC), 1983] and (B) study
design.
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Recurrence pattern was categorized as locoregional recurrence, peritoneal
carcinomatosis, or distant metastasis. Locoregional recurrence was defined
as recurrence in the gastric bed, anastomotic site, regional lymph nodes
(including the paraaortic lymph nodes), or an adjacent structure by direct
extension. Peritoneal carcinomatosis was based on positive cytology in
ascites or visualization of peritoneal nodules by CT scan. Tumors involving
ovaries (Krukenberg’s tumor) were considered to be peritoneal
carcinomatosis. Distant metastasis was defined as specific organ
involvement via systemic metastasis. Periumbilical nodules and extra-
abdominal lymph nodes were considered to be distant metastases. Newly
developed tumors in the stomach remnant, except for the anastomosis site,
were defined as second primary gastric cancers, which were not included
in the definition of recurrence.
statistical methods
The sample size was calculated to provide the study with 80% power to
detect a difference of 18% between 5-year OS rates of chemotherapy alone
and chemoimmunotherapy with a two-sided a value of 0.05. It was
assumed that the expected 5-year OS rate for the control group was 45%.
The minimum sample size for each arm was 131, and assuming a 10% drop
out rate, a final sample size for each arm was calculated to be 145
patients. All P values were two-sided, and the a value was set at 0.05.
Survival was calculated using the Kaplan–Meier method. A log-rank test
was used for multivariate analysis. The chi-square test was used to check the
comparability of patient’s characteristics.
results
patient characteristics
From January 1984 to December 1989, 292 patients were
enrolled. Twelve patients (4.1%) were excluded due to
inadequate staging; five had early gastric cancer (T1N0–2), four
adjacent organ invasion (T4b), and three far advanced lymph
node involvement (N3). For the adjuvant treatment, 142 and
138 patients were randomly assigned to receive chemotherapy
or chemoimmunotherapy, respectively. There were no
differences in age, sex ratio, tumor location, or tumor
differentiation between the two treatment arms. More patients
receiving chemotherapy alone, however, underwent subtotal
gastrectomy (P = 0.019). In all, 26.8% of the chemotherapy
arm were diagnosed as having T2 cancer, as were 29.0% of the
chemoimmunotherapy arm (P = 0.278). In all, 20.4% and
22.5% of those treated by chemotherapy and
chemoimmunotherapy, respectively, were node positive
(P = 0.772; Table 1).
treatment compliance
A complete chemotherapy regimen was administered in 95
patients (66.9%) from arm A and in 95 patients (68.8%) from
arm B (P = 0.561). Chemotherapy was interrupted in 12
patients (8.5%) from arm A and two (1.4%) from arm B due to
recurrence during treatment. In those treated by
chemoimmunotherapy, 87 patients (63.0%) completed
immunotherapy, while 51 patients (37.0%) did not receive the
booster poly A:U.
A median of 12 cycles of adriamycin was delivered to each
arm (chemotherapy: range, 2–12; chemoimmunotherapy:
range, 1–12) (P = 0.317). The planned dose intensities for 5-FU
and adriamycin were 12 mg/kg/week and 13.3 mg/m2/week,
respectively. The median relative dose intensity (RDI) for 5-FU
was 0.94 (range, 0.08–1.00) and 0.97 (range, 0.12–1.00) for
arms A and B, respectively (P = 0.055). The RDI for adriamycin
was 0.87 (range, 0.36–1.00) and 0.91 (range, 0.44–1.00),
respectively, for arms A and B (P = 0.003).
comparison of RFS and OS
With the median follow-up duration of 92 months (range, 7–
260 months), 154 patients died: 87 (61.3%) patients of
chemotherapy arm and 67 (48.6%) of chemoimmunotherapy
arm. One hundred and twenty-eight patients (83.1%) died
from cancer recurrence, six (3.9%) from cerebrovascular
accidents, five (3.3%) from traffic accidents, four (2.6%) from
heart diseases, three (1.9%) from a second primary cancer, and
Chemotherapy (Arm A)
5-fluorouracil 12  mg/kg IV q week for 18 months
Doxorubicin 40 mg/m2 IV q 3 weeks x 12 cycles
Chemoimmunotherapy (Arm B)
Chemotherapy   : Same as Arm A
Immunotherapy : Poly A:U 100 mg IV  q week x 6, 
Staring on day 4 after first chemotherapy, and
50 mg IV  q week x 6, 6 months later
Figure 2. Treatment regimen of chemotherapy and
chemoimmunotherapy.
Table 1. Patient characteristics
Chemotherapy Chemoimmunotherapy
No. of assessable patients 142 138
Age (median) 54 (28–70) 53 (24–70)
Sex (M : F) 1.9 : 1 1.5 : 1
Tumor location, n (%)
Antrum, pylorus 76 (53.5) 86 (62.3)
Body 53 (37.4) 34 (24.6)
Fundus, cardia 9 (6.3) 16 (11.6)
Diffuse 4 (2.8) 2 (1.4)
Tumor differentiation, n (%)
Well differentiated 16 (11.3) 18 (13.0)
Moderately differentiated 26 (18.3) 27 (19.6)
Poorly differentiated 63 (44.4) 56 (40.6)
Signet ring cell 19 (13.4) 21 (15.2)
Undifferentiated 18 (12.6) 16 (11.6)
Type of surgery, n (%)
Subtotal 115 (81.0) 95 (68.8)
Total 27 (19.0) 43 (31.2)
T stage (AJCC, 1983), n (%)
T2 38 (26.8 40 (29.0
T3 12 (8.5) 19 (13.8)
T4a 92 (64.8) 79 (57.2)
N stage (AJCC, 1983), n (%)
N0 29 (20.4) 31 (22.5)
N1 74 (52.1 66 (47.8)
N2 39 (27.5) 41 (29.7)
Tumor stage (AJCC, 1983), n (%)
II 8 (5.6) 7 (5.1)
III 134 (94.4) 131 (94.9)
AJCC, American Joint Cancer Committee.
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eight (5.2%) from other causes. Chemoimmunotherapy arm
had a longer OS compared with chemotherapy arm (68.4%
at 5 years, 55.6% at 10 years, and 50.1% at 15 years versus
52.4% at 5 years, 43.8% at 10 years, and 38.1% at 15 years,
respectively; P = 0.013; Figure 3A).
Tumor recurrence was documented in 131 patients: 77
patients (54.2%) of chemotherapy arm and 54 patients (39.1%)
of chemoimmunotherapy arm. Chemoimmunotherapy arm
had a longer RFS (68.3% at 5 years, 60.3% at 10 years, and
59.4% at 15 years versus 52.1% at 5 years, 46.6% at 10 years,
and 44.1% at 15 years in the chemotherapy arm, respectively;
P = 0.005; Figure 3B). Gastric cancer-specific survival rates
were also higher in chemoimmunotherapy arm (70.3% at 5
years, 61.5% at 10 years, and 61.5% at 15 years versus 55.2% at
5 years, 49.0% at 10 years, and 45.6% at 15 years, respectively,
in chemotherapy arm; P = 0.005).
Subset analyses according to tumor depth (T), lymph node
involvement (N), and stage were carried out retrospectively for
both RFS and OS. Subset analysis was also carried out
according to 2002 AJCC staging [15] to compare these results
with those of recent studies. In the T3, T4a, and N2 subgroups,
definite survival benefits (P < 0.05) were observed with
chemoimmunotherapy when using 1983 or 2002 AJCC staging
criteria. There was a marginal survival benefit in N1 patients of
chemoimmunotherapy (Table 2). Survival benefit was observed
primarily for stage III disease (Figure 3; Table 2).
recurrence pattern and second primary cancer
Of the 77 recurrences in the chemotherapy arm, 53.2% were
peritoneal carcinomatosis and 35.1% recurred in distant
organs. Of the 54 recurrences in the chemoimmunotherapy
arm, 50.0% were peritoneal carcinomatosis and 29.6% recurred
in distant organs.
During the 15-year follow-up, seven and three second
primary cancers arose in the chemotherapy and
chemoimmunotherapy arms, respectively. Colorectal
carcinoma (two patients) and a second primary gastric
carcinoma (two patients) were detected most frequently in arm
A and arm B, respectively.
toxicity profiles
In both arms, the most common non-hematological toxic
effects of the treatments were alopecia, nausea, and vomiting.
Fever was more common in the chemoimmunotherapy arm
(18 versus 3). Grade 3/4 leucopenia was observed in three and
Figure 3. (A) Overall survival and (B) recurrence-free survival based on the American Joint Cancer Committee staging criteria (1983). HR, hazard ratio; CI,
confidence interval; Cix, chemoimmunotherapy; Cx, chemotherapy.
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four patients from the chemotherapy and
chemoimmunotherapy arms, respectively. Grade 3/4 anemia
was observed in three and one patients from each arm,
respectively. There were no treatment-related deaths in either
group (Table 3).
prognostic factors for survival
RFS and OS were analyzed according to age (<40 versus 40–59
versus ‡60 years), sex (male versus female), tumor location
(antrum or pylorus versus body versus fundus or cardia versus
diffuse), tumor differentiation (well versus moderately versus
poorly differentiated or signet ring cell versus undifferentiated),
type of surgery (subtotal versus total), and RDI of
chemotherapy (below median versus above median). Bivariate
analysis indicated significant survival differences (P < 0.05)
according to the tumor differentiation and the RDIs of 5-FU
and adriamycin (data not shown).
On multivariate analysis, the independent prognosticators
for OS were tumor differentiation {P = 0.001; hazard ratio
(HR) = 1.48 [95% confidence interval (CI) 1.18–1.86]} and
treatment arm [P = 0.016; HR = 1.52 (95% CI 1.08–2.14)]. The
independent prognosticators for RFS were tumor
differentiation [P < 0.001; HR = 1.60 (95% CI 1.24–2.08)] and
treatment arm [P = 0.009; HR = 1.66 (95% CI 1.33–2.42)].
discussion
Compared with chemotherapy alone, the addition of the
immunomodulator poly A:U to adjuvant FA chemotherapy
prolonged RFS and OS in patients who had undergone curative
D2 gastrectomy. In terms of gastric cancer-specific survival,
there was a greater survival benefit for chemoimmunotherapy
arm. In patients receiving chemotherapy alone, the 5-year
OS rates ranged widely from 31.0% to 95.7% as the tumor stage
Table 2. Subset analysis of survivals between the chemotherapy (A) and chemoimmunotherapy (B) arms according to AJCC staging (1983 and 2002)
Patient number: arm A/B Median OS (month) (95% CI) Median RFS (month) (95% CI)
Arm A Arm B P value Arm A Arm B P value
AJCC (1983)
T stage
T2 38/40 152 (NA) 178 (NA) 0.879 NR NR 0.614
T3 12/19 31 (11–51) NR 0.011 29 (9–49) NR 0.022
T4a 92/79 53 (20–86) NR 0.029 50 (13–87) NR 0.018
N stage
N0 29/31 NR NR 0.414 NR NR 0.914
N1 74/66 91 (14–168) NR 0.327 NR NR 0.025
N2 39/41 33 (28–38) 85 (0–186) 0.005 20 (11–29) NR 0.036
Stage
II 8/7 58 (0–187) NR 0.055 NR NR 0.502
III 134/131 72 (42–102) 158 (NA) 0.031 69 (0–146) NR 0.006
AJCC (2002)
T stage
T1–2 85/38 NR NR 0.674 NR NR 0.929
T3–4 57/100 28 (20–36) NR <0.001 20 (14–26) NR <0.001
N stage
N0 28/31 166 (NA) NR 0.381 NR NR 0.937
N1 71/59 159 (NA) NR 0.083 NR NR 0.033
N2 30/29 32 (27–37) 85 (20–150) 0.014 20 (11–29) NR 0.005
N3 13/17 35 (12–58) 34 (0–68) 0.813 26 (13–39) 23 (12–34) 0.627
Stage
IB 18/5 NR NR 0.639 NR NR 0.358
II 53/45 159 (NA) NR 0.394 NR NR 0.379
IIIA 47/51 39 (20–58) NR <0.001 26 (14–38) NR <0.001
IIIB 12/20 16 (4–28) 53 (0–110) 0.003 12 (4–20) 41 (NA) 0.007
IV 12/17 34 (2–66) 34 (0–68) 0.757 26 (11–41) 23 (12–34) 0.702
Gray areas are subgroups displaying significant survival advantages of chemoimmunotherapy over chemotherapy alone.
AJCC, American Joint Cancer Committee; OS, overall survival; CI, confidence interval; RFS, recurrence-free survival; NA, not assessable; NR, not reached.
Table 3. Incidences of severe (grade III/IV) toxicity by patients
Toxic effects Chemotherapy Chemoimmunotherapy
No. of patients No. of patients
Total Grade III/IV Total Grade III/IV
Alopecia 118 3 119 1
Nausea/vomiting 111 5 106 4
Diarrhea 46 8 40 4
Mucositis 57 3 62 3
Anemia 94 3 84 1
Leukopenia 105 3 104 4
Skin pigmentation 57 0 58 0
Infection 20 1 15 1
Fever 3 0 18 0
original article Annals of Oncology
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increased from IB to IVM0. These survival rates are similar
to those of other trials with Asian patients [16, 17]. The
addition of poly A:U to standard chemotherapy reduced the
risk of recurrence and cancer-related death by 16% at 5 years.
The clinical relevance is evident from the fact that this risk
reduction was maintained for 15 years after surgery. This is the
first randomized trial to demonstrate a survival benefit of
poly A:U as an adjuvant immunotherapy for gastric cancer
which was maintained after long-term follow-up period.
The antitumor mechanism of poly A:U is complex.
Researchers who successfully demonstrated an effect of
adjuvant poly A:U in breast cancer suggested that one of the
important mechanisms is tumor cell death through an
activation of natural killer (NK) cells [18]. We also
demonstrated that NK cell activity is enhanced after the
administration of poly A:U [19]. This NK-boosting effect of
poly A:U is mediated by interferon induction and lymphokine-
activated killer cell activation [18]. Moreover, although
chemotherapy is generally considered an immunosuppressant,
in this study chemotherapy did not act as an
immunosuppressant when combined with the
immunomodulator, poly A:U. Paclitaxel enhances the
antibody-dependent cell-mediated cytotoxicity of trastuzumab
by a rapid recruitment of NK cells, the effect of which is
twice as strong as trastuzumab alone [20]. These findings may
reflect the strong synergistic effect of the combination of the
drugs with different action mechanisms and indicate a rationale
for chemobiotherapy or chemoimmunotherapy in designing
future trials.
In reviewing the results of previous adjuvant studies, there
were some factors identified that may have negatively
affected the efficacy of adjuvant therapy on survival. First, since
a large number of institutions have participated in adjuvant
trials, there may be no standard surgical technique which is
common across these institutions [21, 22]. Thus, the effects of
adjuvant therapy cannot be compared adequately, considering
that successful curative surgery is the single most important
factor in prognosis. If patients with palliative resection were
included in adjuvant trials, the efficacy of adjuvant therapy
would thus be likely underestimated. Because limited
lymphadenectomies increase the chance of residual tumor after
the resection, D2 or D3 resection has been carried out as
a standard curative surgery in Asia, especially in Korea and
Japan. For this reason, we also carried out standardized D2 or
D3 resection in this study. Secondly, the eligibility criteria of
earlier adjuvant trials also included heterogeneous categories of
pathological stages ranging from stage I to stage IV disease
(N3 or T4b) [21–23]. In earlier Asian trials, subset analyses
indicated that the survival benefit was greatest in stage II and III
patients or in stage III patients [24, 25]. On the basis of these
results, we excluded the early- (T1) and advanced-stage (T4b,
N3) cancer. We think proper patient selection and standardized
extended surgery may have contributed to the illustration
of efficacy of adjuvant chemoimmunotherapy in this trial.
Most Western studies on adjuvant chemotherapy for gastric
cancer have reported negative results, whereas Asian trials have
tended to favor adjuvant chemotherapy [3, 4]. In the 1980s,
Korean and Japanese researchers were so convinced that
adjuvant chemotherapy improved survival in gastric cancer,
especially for extended lymphadenectomized patients, and that
a randomized trial comparing adjuvant therapy versus surgery
alone was considered unethical. Therefore, we designed this
trial comparing chemoimmunotherapy versus chemotherapy.
In a recent randomized phase III trial of stage II/III gastric
cancer patients, adjuvant S-1 monotherapy gave a survival
benefit over surgery alone after D2 gastrectomy [26]. For
advanced gastric cancer, S-1 plus cisplatin was superior to S-1
monotherapy [27]. On the basis of these results, we are
considering switching the adjuvant trial regimen to an S-1-
based regimen.
Here, we did not stratify patients according to the T or N
status. Therefore, there were more T4a patients and fewer T2
patients in the chemotherapy group compared with
chemoimmunotherapy group. These differences, however, were
not statistically significant. Differences in the distribution of
potential prognosticators between the two treatment arms were
observed only for surgery type, not for age, sex ratio, tumor
location, or tumor differentiation. Some studies have reported
survival benefits of adjuvant chemotherapy in selected
subgroups with node-positive T2/T3/T4 or stage III tumors
[22, 23, 28]. In our study, the subset analyses according to
tumor depth (T) and lymph node involvement (N) were also
similar; survival benefits of chemoimmunotherapy over
chemotherapy alone were observed in moderately advanced
stages such as T3/T4a, N2, or stage III. Also, the N1 patients
receiving chemoimmunotherapy showed a borderline survival
benefit. Several adjuvant chemoimmunotherapy trials using
other immunomodulators for gastric cancer also showed
survival benefit over chemotherapy alone in patients with pT2/
T3 or stage III tumors.[29, 30] These data indicate that stage-
oriented adjuvant chemotherapy or chemoimmunotherapy
regimens may be imperative in the future.
Chemoimmunotherapy was well tolerated in general.
Immunotherapy did not disturb the administration of
chemotherapy. As a result, a similar number of patients
completed chemotherapy in both arms (66.9% versus
68.8%). Also, no major differences in toxicity were noted
between the two treatment arms. Long-term cardiac events
were evaluated in this study. Four patients died from heart
disease; two of these from myocardial infarction (29, 155
months), one from arrhythmia (109 months), and one from
CHF (109 months). Some patients receiving 100 mg of poly
A:U in 20 ml saline exhibited a temporary fever (<38C)
lasting several hours. In later studies, however, fever was
rarely observed when the same dosage of the poly A:U was
administered in 50 ml instead of 20 ml of saline.
To conclude, in resectable gastric cancer, adjuvant
chemoimmunotherapy with FA and poly A:U conferred
a survival benefit over chemotherapy alone during a 15-year
follow-up. Chemoimmunotherapy was found to be as tolerable
as chemotherapy alone.
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